pyridoxine has been researched along with Erythema in 9 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 7.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis." | 5.14 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 3.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeung, HC | 1 |
| Chung, HC | 1 |
| Chalermchai, T | 1 |
| Tantiphlachiva, K | 1 |
| Suwanrusme, H | 1 |
| Voravud, N | 1 |
| Sriuranpong, V | 1 |
| von Moos, R | 1 |
| Thuerlimann, BJ | 1 |
| Aapro, M | 1 |
| Rayson, D | 1 |
| Harrold, K | 1 |
| Sehouli, J | 1 |
| Scotte, F | 1 |
| Lorusso, D | 1 |
| Dummer, R | 1 |
| Lacouture, ME | 1 |
| Lademann, J | 1 |
| Hauschild, A | 1 |
| Rossi, D | 1 |
| Catalano, G | 1 |
| Vukelja, SJ | 1 |
| Baker, WJ | 1 |
| Burris, HA | 1 |
| Keeling, JH | 1 |
| Von Hoff, D | 1 |
| Tanaka, M | 1 |
| Niizeki, H | 1 |
| Shimizu, S | 1 |
| Miyakawa, S | 1 |
| Fabian, CJ | 1 |
| Molina, R | 1 |
| Slavik, M | 1 |
| Dahlberg, S | 1 |
| Giri, S | 1 |
| Stephens, R | 1 |
| Schmutz, JL | 1 |
| Cuny, JF | 1 |
| Trechot, P | 1 |
| Weber, M | 1 |
| Beurey, J | 1 |
| Ishibashi, A | 1 |
| Hirano, K | 1 |
| Nishiyama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pyridoxine and Erythema
| Article | Year |
|---|---|
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
8 other studies available for pyridoxine and Erythema
| Article | Year |
|---|---|
Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erythema; Fl | 2010 |
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
Topics: Adrenal Cortex Hormones; Dermatologic Agents; Doxorubicin; Drug Eruptions; Erythema; Foot Dermatoses | 2008 |
Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Clinical Trials as Topic; Doxorubicin; Erythema; | 2007 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Hu | 1993 |
Photoallergic drug eruption due to pyridoxine hydrochloride.
Topics: Aged; Dermatitis, Photoallergic; Drug Eruptions; Erythema; Humans; Male; Patch Tests; Pyridoxine; Th | 1996 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Topics: Colonic Neoplasms; Edema; Erythema; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatose | 1990 |
[Drug-induced pellagroid erythema. A case of pellagroid erythema caused by isoniazide].
Topics: Antineoplastic Agents; Erythema; Ethionamide; Female; Humans; Isoniazid; Middle Aged; Monoamine Oxid | 1987 |
Photosensitive dermatitis due to pyritinol.
Topics: Administration, Oral; Biopsy; Dermatitis, Exfoliative; Drug Eruptions; Erythema; Humans; Lichen Plan | 1973 |